我院2014-2015年麝香通心滴丸的用药合理性评价
x
请在关注微信后,向客服人员索取文件
篇名: | 我院2014-2015年麝香通心滴丸的用药合理性评价 |
TITLE: | |
摘要: | 目的:为麝香通心滴丸的临床合理使用提供参考。方法:采用回顾性研究方法,对我院2014年1月-2015年5月使用麝香通心滴丸的门诊及住院患者的性别、年龄、处方科室、不合理用药情况、不良反应发生情况和药物利用指数(DUI)等进行统计分析。结果:共收集门诊处方719张,住院医嘱281份。使用麝香通心滴丸的患者女性多于男性,男女比例为1 ∶ 1.42;患者年龄以80~89岁居多(占35.4%)。麝香通心滴丸的使用科室以心血管内科居多,有760张/份(占76.0%)。适应证不符的处方/医嘱有72张/份(占7.2%),超剂量使用的处方/医嘱有7张/份(占0.7%)。未见明显药品不良反应发生。麝香通心滴丸的DUI为1.007。结论:我院麝香通心滴丸临床使用基本合理,但仍存在不规范使用现象。建议严格按照麝香通心滴丸药品说明书合理使用,同时加强辨证论治,以减少和避免不良反应的发生。 |
ABSTRACT: | OBJECTIVE: To provide reference for rational use of Shexiang tongxin dripping pills in clinic. METHODS: In retrospective study, the utilization of Shexiang tongxin dripping pills in outpatients and inpatients of our hospital during Jan. 2014-May 2015 was analyzed statistically in terms of gender, age, department, irrational drug use, ADR and DUI, etc. RESULTS: There were 719 outpatient prescriptions and 281 inpatient medical orders. The female was more than male with ratio of 1.42 ∶ 1. Most patients aged 80-89 year-old (35.4%). Shexiang tongxin dripping pills were mostly used in cardiovascular medicine department (760 pieces/copies, 76.0%). There were 72 prescriptions/medical orders that did not conform to the indications (7.2%), and 7 prescriptions/medical orders for overdose use (0.7%). No obvious ADR was found. DUI of Shexiang tongxin dripping pills was 1.007. CONCLUSIONS: Although the clinical use of Shexiang tongxin dripping pills in our hospital is basically rational, there still are some nonstandard uses, which should be taken seriously. In order to reduce ADR, the clinical use of Shexiang tongxin dripping pills should be strictly in accordance with the drug instructions and should emphasize the syndrome differentiation based on treatment. |
期刊: | 2017年第28卷第23期 |
作者: | 王丹丹,黄巧玲,吴晓云,何新军 |
AUTHORS: | WANG Dandan,HUANG Qiaoling,WU Xiaoyun,HE Xinjun |
关键字: | 麝香通心滴丸;合理用药;心血管疾病 |
KEYWORDS: | Shexiang tongxin dripping pills; Rational drug use; Cardiovascular diseases |
阅读数: | 445 次 |
本月下载数: | 6 次 |
* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!